Try Benzinga Pro FREE with a 14 day trial: Take your trading to the next level with our suite of premium research services and tools: Find more market-moving insights at your one-stop destination for ...

The FDA’s Breakthrough Devices Program is designed to accelerate development and review of devices that offer meaningful advances in care for serious or life-threatening conditions. With more than ...

Below, George Newman shares five key insights from his new book, How Great Ideas Happen: The Hidden Steps Behind Breakthrough Success. Most of us think great ideas are conjured from within—some ...

Sepsis is one of the leading causes of death and disability worldwide. It can affect anyone, and is notoriously difficult to diagnose in the early stages, and to treat once it becomes life-threatening ...

GENEVA (AP) — The latest U.S.-brokered talks between envoys from Moscow and Kyiv over Russia's all-out invasion of Ukraine ended Wednesday with no sign of a breakthrough and with both sides saying the ...

Breakthrough Energy, the Bill Gates-backed group that bankrolls climate tech, has stopped making new investments from one of its key funds to scale up nascent green technologies, just as the market ...

Breakthrough Energy, the Bill Gates-backed group that bankrolls climate tech, has stopped making new investments from one of its key funds to scale up nascent green technologies, just as the market ...

Sustainability: News about the rapidly growing climate tech sector and other areas of innovation to protect our planet. SEE MORE by Lisa Stiffler on Feb 13, 2026 at 9:47 am February 13, 2026 at 5:03 ...

Sanofi’s investigational therapy rilzabrutinib has received breakthrough therapy designation from the FDA for the treatment of warm autoimmune hemolytic anemia. The designation is based on data from ...

The Breakthrough T1D San Francisco Gala returns for its 27th year, bringing the T1D community together for "A Magical Night Beneath the Cherry Blossoms" at the iconic San Francisco City Hall. This ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...

Breakthrough therapy designation targets the post-CDK4/6 setting in PIK3CA-mutant HR+/HER2− advanced disease, where progression is common and therapeutic options remain constrained. Phase 1/2 ...